Why Orchid Pharma Shares Gained On Wednesday?
In an exchange filing on Tuesday, Orchid Pharma said that it has signed a licensing and supply agreement with Pharmasyntez JSC, to commercialise the Exblifep in Russia.
Exblifep is a novel combination antibiotic, used for the treatment of complicated Urinary Tract Infections (cUTIs), and hospital-acquired and ventilator-associated bacterial pneumonia (HAP/VAP) caused by the gram-negative bacterial pathogens.
This agreement is subject to regulatory approval from the Ministry of Health of the Russian Federation.
As part of this agreement, Pharmasyntez will hold the exclusive rights to register and commercialise Exblifep in Russia, with Orchid Pharma supplying the finished dosage form.
“The partnership represents a potential opportunity of approximately $178 million over the first 10 years,” Orchid Pharma said in its filing, reflecting the scale of unmet clinical need and significant hospital procurement volumes in Russia.
Exblifep is approved by the USFDA and the European Medicines Agency, and is also included in the IDSA and EUCAST treatment guidelines. It is also the first new chemical entity originating from an Indian pharmaceutical company to receive both approvals.
Orchid’s partnership with Pharmasyntez marks an important step in making Exblifep available to patients in Russia, according to Orchid Pharma Managing Director Manish Dhanuka.
Shares of Orchid Pharma are trading 9.2% higher on Wednesday after the announcement at 1,006.85. The stock has risen 20% in the last one month itself, taking its year-to-date advance to 27%.
First Published: Jul 8, 2026 10:23 AM IST
